Dr. Laszlo Radvanyi

Dr. Radvanyi is a seasoned cancer immunotherapy expert, who has had a primary focus on cell therapy and cytokine treatments for over two decades. He holds a Ph.D. in Clinical Biochemistry from the University of Toronto, with research centered on programmed cell death and T cell tolerance regulation in immunology. Currently, he serves as the President & Scientific Director of the Ontario Institute for Cancer Research (OICR), overseeing a vast research team and guiding the institute's scientific strategy. He is also a Professor at the University of Toronto's Department of Immunology. His research concentrates on immune-cancer interactions in breast cancer progression and the role of retroelements and endogenous retroviruses in cancer immunoregulation. In the past, Dr. Radvanyi held the position of Senior Vice President, Global Head of Immuno-Oncology at EMD Serono, where he revamped and organized the Immuno-Oncology research platform and contributed to the development of a groundbreaking biologic agent for cancer treatment. Prior to this, he conducted influential research in cancer immunotherapy at MD Anderson Cancer Center and co-founded Iovance Biotherapeutics, a biotech company specializing in TIL therapies for cancer, where he played a pivotal role as its founding CSO in recruitment, infrastructure development, and clinical trial initiation.